Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ALNY Alnylam Pharmaceuticals	$325.00 +3.8%	$280.97	$205.87 ▼ $326.03	$40.83B	0.22	895,229 shs	1.00 million shs
BIIB Biogen	$126.31 +1.2%	$125.13	$110.04 ▼ $238.00	$18.28B	0.14	1.42 million shs	938,157 shs
BMRN BioMarin Pharmaceutical	$54.69 +1.1%	$58.66	$52.93 ▼ $94.85	$10.37B	0.19	1.71 million shs	2.27 million shs
UTHR United Therapeutics	$289.94 +1.2%	$301.13	$266.98 ▼ $417.82	$12.92B	0.57	449,987 shs	364,688 shs

7 Stocks to Buy And Hold Forever

Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ALNY Alnylam Pharmaceuticals	+3.79%	+5.28%	+12.08%	+20.72%	+45.81%
BIIB Biogen	+1.24%	-0.20%	+0.40%	-11.32%	-44.26%
BMRN BioMarin Pharmaceutical	+1.13%	-0.56%	-4.97%	-23.49%	-35.76%
UTHR United Therapeutics	+1.24%	+1.07%	-5.76%	-6.72%	-9.09%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ALNY Alnylam Pharmaceuticals	4.1876 of 5 stars	2.4	5.0	4.3	2.7	2.5	0.6
BIIB Biogen	4.8064 of 5 stars	4.2	3.0	3.7	2.6	1.7	2.5
BMRN BioMarin Pharmaceutical	4.9687 of 5 stars	3.4	5.0	3.3	2.7	2.5	4.4
UTHR United Therapeutics	4.9886 of 5 stars	4.3	5.0	4.6	2.9	3.3	2.5

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ALNY Alnylam Pharmaceuticals	2.79	Moderate Buy	$335.32	3.17% Upside
BIIB Biogen	2.38	Hold	$188.19	48.99% Upside
BMRN BioMarin Pharmaceutical	2.74	Moderate Buy	$93.45	70.88% Upside
UTHR United Therapeutics	2.69	Moderate Buy	$393.08	35.57% Upside

Current Analyst Ratings Breakdown

Latest BMRN, ALNY, BIIB, and UTHR Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/24/2025	ALNY Alnylam Pharmaceuticals	BMO Capital Markets Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$300.00 ➝ $360.00
6/12/2025	ALNY Alnylam Pharmaceuticals	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$330.00 ➝ $338.00
6/12/2025	BIIB Biogen	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Neutral ➝ Neutral	$115.00
6/12/2025	BIIB Biogen	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Neutral ➝ Neutral	$121.00
6/12/2025	BIIB Biogen	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Hold ➝ Hold
6/11/2025	UTHR United Therapeutics	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Neutral ➝ Neutral	$321.00 ➝ $315.00
6/2/2025	UTHR United Therapeutics	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Overweight	$405.00
5/7/2025	BIIB Biogen	Mizuho Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$207.00 ➝ $169.00
5/5/2025	BIIB Biogen	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Neutral ➝ Neutral	$185.00 ➝ $175.00
5/5/2025	BMRN BioMarin Pharmaceutical	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$124.00 ➝ $104.00
5/5/2025	UTHR United Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$425.00 ➝ $425.00

(Data available from 6/25/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ALNY Alnylam Pharmaceuticals	$2.25B	18.85	N/A	N/A	$0.52 per share	625.00
BIIB Biogen	$9.68B	1.91	$23.39 per share	5.40	$114.71 per share	1.10
BMRN BioMarin Pharmaceutical	$2.85B	3.68	$3.28 per share	16.66	$29.69 per share	1.84
UTHR United Therapeutics	$2.88B	4.55	$28.74 per share	10.09	$144.34 per share	2.01

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ALNY Alnylam Pharmaceuticals	-$278.16M	-$2.09	N/A	365.17	N/A	-11.49%	-510.31%	-6.48%	7/30/2025 (Estimated)
BIIB Biogen	$1.63B	$10.13	12.47	7.65	0.99	15.07%	14.03%	8.32%	7/30/2025 (Estimated)
BMRN BioMarin Pharmaceutical	$426.86M	$2.69	20.33	12.54	0.74	17.76%	11.34%	8.95%	8/4/2025 (Estimated)
UTHR United Therapeutics	$1.20B	$25.06	11.57	10.55	6.27	40.44%	19.33%	16.73%	7/30/2025 (Estimated)

Latest BMRN, ALNY, BIIB, and UTHR Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/1/2025	Q1 2025	ALNY Alnylam Pharmaceuticals	-$0.37	-$0.44	-$0.07	-$0.44	$584.32 million	$594.19 million
5/1/2025	Q1 2025	BIIB Biogen	$3.26	$3.02	-$0.24	$1.64	$2.25 billion	$2.43 billion
4/30/2025	Q1 2025	UTHR United Therapeutics	$6.29	$6.63	+$0.34	$6.63	$726.82 million	$794.40 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ALNY Alnylam Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
BIIB Biogen	N/A	N/A	N/A	N/A	N/A
BMRN BioMarin Pharmaceutical	N/A	N/A	N/A	N/A	N/A
UTHR United Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ALNY Alnylam Pharmaceuticals	8.88	3.04	2.98
BIIB Biogen	0.27	1.44	1.01
BMRN BioMarin Pharmaceutical	0.10	5.52	3.49
UTHR United Therapeutics	N/A	5.46	5.23

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ALNY Alnylam Pharmaceuticals	92.97%
BIIB Biogen	87.93%
BMRN BioMarin Pharmaceutical	98.71%
UTHR United Therapeutics	94.08%

Insider Ownership

Company	Insider Ownership
ALNY Alnylam Pharmaceuticals	1.20%
BIIB Biogen	0.18%
BMRN BioMarin Pharmaceutical	0.85%
UTHR United Therapeutics	10.30%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ALNY Alnylam Pharmaceuticals	2,230	130.39 million	128.82 million	Optionable
BIIB Biogen	7,605	146.53 million	146.26 million	Optionable
BMRN BioMarin Pharmaceutical	3,040	191.78 million	190.15 million	Optionable
UTHR United Therapeutics	1,305	45.11 million	40.46 million	Optionable

BMRN, ALNY, BIIB, and UTHR Headlines

Recent News About These Companies

Oppenheimer Asset Management Inc. Has $5.28 Million Stock Position in United Therapeutics Corporation (NASDAQ:UTHR)

June 25 at 4:19 AM | marketbeat.com

United Therapeutics and Intermountain Health Announce the First Patient Treated With External Liver Support Using a Bioengineered Liver

June 24 at 5:00 PM | bakersfield.com

United Therapeutics’ Ralinepag Study: A Potential Game-Changer for PAH Treatment

June 24 at 12:51 PM | tipranks.com

United Therapeutics Corporation Concludes Enrollment of the ADVANCE OUTCOMES Study of Ralinepag for the Treatment of Pulmonary Arterial Hypertension

June 23 at 7:00 AM | businesswire.com

United Therapeutics Corporation (NASDAQ:UTHR) Receives Average Recommendation of "Moderate Buy" from Analysts

June 23 at 2:26 AM | marketbeat.com

Retirement Systems of Alabama Sells 11,423 Shares of United Therapeutics Corporation (NASDAQ:UTHR)

June 21, 2025 | marketbeat.com

CWA Asset Management Group LLC Raises Holdings in United Therapeutics Corporation (NASDAQ:UTHR)

June 19, 2025 | marketbeat.com

United Therapeutics Corporation (NASDAQ:UTHR) EVP Sells $3,079,560.00 in Stock

June 19, 2025 | americanbankingnews.com

Great Lakes Retirement Inc. Acquires Shares of 4,014 United Therapeutics Co. (NASDAQ:UTHR)

June 17, 2025 | marketbeat.com

United Therapeutics Co. (NASDAQ:UTHR) EVP Sells $3,079,560.00 in Stock

June 17, 2025 | insidertrades.com

Paul A. Mahon Sells 11,000 Shares of United Therapeutics Co. (NASDAQ:UTHR) Stock

June 16, 2025 | marketbeat.com

328,783 Shares in United Therapeutics Co. (NASDAQ:UTHR) Bought by Vaughan Nelson Investment Management L.P.

June 15, 2025 | marketbeat.com

SG Americas Securities LLC Grows Stock Holdings in United Therapeutics Co. (NASDAQ:UTHR)

June 14, 2025 | marketbeat.com

Tobam Sells 11,834 Shares of United Therapeutics Co. (NASDAQ:UTHR)

June 13, 2025 | marketbeat.com

3,900 Shares in United Therapeutics Co. (NASDAQ:UTHR) Purchased by Polianta Ltd

June 13, 2025 | marketbeat.com

Greenwood Capital Associates LLC Acquires Shares of 2,349 United Therapeutics Co. (NASDAQ:UTHR)

June 13, 2025 | marketbeat.com

Assenagon Asset Management S.A. Purchases 10,290 Shares of United Therapeutics Co. (NASDAQ:UTHR)

June 13, 2025 | marketbeat.com

United Therapeutics (UTHR) Soars 3.5%: Is Further Upside Left in the Stock?

June 13, 2025 | zacks.com

United Therapeutics (NASDAQ:UTHR) Price Target Cut to $315.00 by Analysts at Bank of America

June 11, 2025 | marketbeat.com

United Therapeutics: Tanking On Rival's PAH Data - I'd Consider Buying Stock

June 11, 2025 | seekingalpha.com

United Therapeutics: Strong Market Position and Growth Potential Amidst Emerging Competition

June 11, 2025 | tipranks.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

BMRN, ALNY, BIIB, and UTHR Company Descriptions

Alnylam Pharmaceuticals NASDAQ:ALNY

$325.00 +11.87 (+3.79%)

Closing price 06/24/2025 04:00 PM Eastern

Extended Trading

$324.94 -0.06 (-0.02%)

As of 06/24/2025 07:20 PM Eastern

Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1. In addition, the company develops patisiran for the treatment of transthyretin amyloidosis, or ATTR amyloidosis, with cardiomyopathy; cemdisiran to treat complement-mediated diseases; Belcesiran for the treatment of alpha-1 liver disease; Elebsiran to treat chronic HBV infection; Zilebesiran to treat hypertension; ALN-APP to treat Alzheimer's disease and cerebral amyloid angiopathy; and ALN-HSD to treat NASH. Further, it offers Fitusiran for the treatment of hemophilia, Inclisiran to treat hypercholesterolemia, lumasiran for the treatment of advanced PH1, and vutrisiran for the treatment of ATTR amyloidosis, which is in phase 3 clinical trial. Alnylam Pharmaceuticals, Inc. has strategic collaborations with Regeneron Pharmaceuticals, Inc. to discover, develop, and commercialize RNAi therapeutics for a range of diseases by addressing therapeutic targets expressed in the eye and CNS; and Roche to develop pharmaceutical products containing zilebesiran. It also has license and collaboration agreements with Novartis AG; Vir Biotechnology, Inc.; Dicerna Pharmaceuticals, Inc.; Ionis Pharmaceuticals, Inc.; and PeptiDream, Inc. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts.

Biogen NASDAQ:BIIB

$126.31 +1.55 (+1.24%)

Closing price 06/24/2025 04:00 PM Eastern

Extended Trading

$127.38 +1.07 (+0.85%)

As of 04:09 AM Eastern

Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; ADUHELM to treat Alzheimer's disease; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE; and BYOOVIZ, a ranibizumab biosimilar referencing LUCENTIS. It offers RITUXAN for treating non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; OCREVUS for relapsing MS and primary progressive MS; LUNSUMIO to treat relapsed or refractory follicular lymphoma; glofitamab for non-Hodgkin's lymphoma; and other anti-CD20 therapies. In addition, the company is developing various products for the treatment of MS, Alzheimer's disease and dementia, neuromuscular disorders, Parkinson's disease and movement disorders, neuropsychiatry, genetic neurodevelopmental disorders, and biosimilars, which are under various stages of development. It has collaboration and license agreements with Acorda Therapeutics, Inc.; Alkermes Pharma Ireland Limited; Denali Therapeutics Inc.; Eisai Co., Ltd.; Genentech, Inc.; Neurimmune SubOne AG; Ionis Pharmaceuticals, Inc.; Samsung Bioepis Co., Ltd.; Sangamo Therapeutics, Inc.; and Sage Therapeutics, Inc., as well as collaboration with Fujirebio to potentially identify and develop blood-based biomarkers for tau pathology in the brain. The company was founded in 1978 and is headquartered in Cambridge, Massachusetts.

BioMarin Pharmaceutical NASDAQ:BMRN

$54.69 +0.61 (+1.13%)

Closing price 06/24/2025 04:00 PM Eastern

Extended Trading

$55.00 +0.31 (+0.57%)

As of 04:00 AM Eastern

BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease. The company's commercial products also comprise Palynziq, a PEGylated recombinant phenylalanine ammonia lyase enzyme, which is delivered through subcutaneous injection to reduce blood Phe concentrations; Brineura, a recombinant human tripeptidyl peptidase 1 for the treatment of patients with ceroid lipofuscinosis type 2, a form of Batten disease; Voxzogo, a once daily injection analog of c-type natriuretic peptide for the treatment of achondroplasia; and Aldurazyme, a purified protein designed to be identical to a naturally occurring form of the human enzyme alpha-L-iduronidase. In addition, it develops Roctavian, an adeno associated virus vector, for the treatment of patients with severe hemophilia A. The company serves specialty pharmacies, hospitals, and non-U.S. government agencies, as well as distributors and pharmaceutical wholesalers in the United States, Europe, Latin America, and internationally. BioMarin Pharmaceutical Inc. has license and collaboration agreements with Sarepta Therapeutics, Ares Trading S.A., Catalyst Pharmaceutical Partners, Inc. The company was incorporated in 1996 and is headquartered in San Rafael, California.

United Therapeutics NASDAQ:UTHR

$289.94 +3.55 (+1.24%)

Closing price 06/24/2025 04:00 PM Eastern

Extended Trading

$288.14 -1.80 (-0.62%)

As of 06/24/2025 05:59 PM Eastern

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients. It also markets and sells Unituxin (dinutuximab) injection, a monoclonal antibody for treating high-risk neuroblastoma; and Remunity Pump, which contains a pump and separate controller for Remodulin. In addition, the company engages in developing RemoPro and Ralinepag for the treatment of PAH; Aurora-GT, a gene therapy product to rebuild the blood vessels in the lungs; and Nebulized Tyvaso, for the treatment of idiopathic pulmonary fibrosis, as well as xenografts, which are development-stage organ products. It has licensing and collaboration agreements with DEKA Research & Development Corp. to develop a semi-disposable system for the subcutaneous delivery of treprostinil; MannKind Corporation to develop and license treprostinil inhalation powder and the Dreamboat device; and Arena Pharmaceuticals, Inc. to develop Ralinepag. The company was incorporated in 1996 and is headquartered in Silver Spring, Maryland.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time